Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atorvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 3/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.98 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.98 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.98 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.84 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.84 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.84 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.84 |
| ▸ | RHOC | P08134 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | THRB | P10828 | 1/20 | 0.84 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.84 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.84 |
| ▸ | PDE6D | O43924 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atorvastatin SCHEMBL28456 | 1.00 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL27701543 | 1.00 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL27850403 | 1.00 | ABCB11 (0.98) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL249095 | 0.99 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL3320399 | 0.99 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL137843 | 0.99 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL909379 | 0.99 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL28018746 | 0.99 | ABCB11 (0.97) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL3832 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 | |
| Atorvastatin SCHEMBL6064039 | 0.99 | ABCB11 (1.00) | ABCB11SLCO1B1ABCC3ABCC4SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280468-A1 | METHOD FOR PREVENTING OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-09-08 | — | — | US | claimed |
| CN-114555605-A | Polymorphs of acraprinib and processes for making the same | 庄信万丰股份有限公司 | 2022-05-27 | — | — | CN | claimed |
| US-20210379004-A1 | METHOD FOR PREVENTING OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2021-12-09 | — | — | US | claimed |
| US-20170273928-A1 | COMPOSITION FOR PREVENTING THE OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2017-09-28 | — | — | US | claimed |
| US-9700537-B2 | Composition for preventing the occurrence of cardiovascular event in multiple risk patient | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2017-07-11 | — | — | US | claimed |
| US-20170151206-A1 | COMPOSITION FOR PREVENTING THE OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2017-06-01 | — | — | US | claimed |
| CN-102526733-B | Composition for preventing onset and/or recurrence of cardiovascular events | MOCHIDA PHARM CO LTD | 2014-09-03 | — | — | CN | claimed |
| CN-101217952-B | Composition for preventing the onset of cardiovascular events | MOCHIDA PHARM CO LTD | 2014-03-12 | — | — | CN | claimed |
| US-8367725-B2 | Composition and/or method for preventing onset and/or recurrence of cardiovascular events | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | claimed |
| CN-102526733-A | Composition for preventing onset and/or recurrence of cardiovascular events | MOCHIDA PHARM CO LTD | 2012-07-04 | — | — | CN | claimed |
| US-20040242899-A1 | Crystalline forms VI and VII of atrovastatin calcium | REDDY SATYANARAYANA (IN) | 2004-12-02 | — | — | US | claimed |
| EP-1472220-A1 | CRYSTALLINE (R-(R*,R*))-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-1H-PYRROLE-HEPTANOIC ACID CALCIUM SALT (2:1) | Ivax C.R., a.s. (CZ) | 2004-11-03 | — | — | EP | claimed |
| EP-1414796-A1 | CRYSTALLINE FORMS VI AND VII OF ATORVASTATIN CALCIUM | Dr. Reddy's Laboratories Ltd. (IN) | 2004-05-06 | — | — | EP | claimed |
| WO-2003050085-A1 | CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-HEPTANOIC ACID CALCIUM SALT (2:1) | IVAX CORPORATION (US) | 2003-06-19 | — | — | WO | claimed |
| WO-2003011826-A1 | CRYSTALLINE FORMS VI AND VII OF ATORVASTATIN CALCIUM | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-02-13 | — | — | WO | claimed |
| CN-1087288-C | Crystalline [R-(R',R')]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(5-methylethyl)-3-phenyl-4-(phenylamino) carbonyl]-1H-pyrole-1-heptanoic acid hemi calcium salt (atorvastatin) | WARNER LAMBERT CO (US) | 2002-07-10 | — | — | CN | claimed |
| EP-0848705-B1 | CRYSTALLINE R-(R*,R*)]-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4- (PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID HEMI CALCIUM SALT (ATORVASTATIN) | WARNER LAMBERT CO (US) | 2001-11-07 | — | — | EP | claimed |
| EP-0848704-B1 | FORM III CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-BETA-DELTA-DIHYDROXY-5-(1-METHYL-ETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID HEMI CALCIUM SALT (ATORVASTATIN) | WARNER LAMBERT CO (US) | 2001-10-24 | — | — | EP | claimed |
| US-6121461-A | ATORVASTATIN HYDRATE; HMG-COA REDUCTASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-09-19 | — | — | US | claimed |
| US-5969156-A | HYPOLIPIDEMIC AND HYPOCHOLESTEROLEMIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-10-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242899-A1 | Crystalline forms VI and VII of atrovastatin calcium | ANXA6, FABP3, HMGCR | HMGCR 3/4885ABCB11 3456/4885SLCO1B1 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.